-
Most Recent
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
Novartis Wins Approval for Breast Cancer Drug
The FDA has granted approval for Novartis' drug Afinitor to be used as a treatment for breast cancer after it showed promise in clinical trials.
Will Vivus Repeat Arena’s Non-Response?
Two days don't make or break a stock, but Vivus' response to Qsymia's approval is far from encouraging. The time to buy might be long past.
Divided, This Rally Cannot Stand!
The fact that Thursday's rally was restricted to just several sectors following a breakout means a slight correction could be due. Watch for new entry points.
7 Long-Term Demographic Trends to Play
Earnings and stock fundamentals are important, but don't miss the forest while looking at the trees. Here are the big-picture demographic trends to keep your eye on.
9 Biotech Buyout Players to Watch
The deal between Human Genome Sciences and GlaxoSmithKline is just the most recent of big pharma buyouts -- and these biotech players could be next.
HGSI Holdout Proves Profitable — for Bagels
Joint pharmaceutical developers Human Genome and GlaxoSmithKline agreed to a sweetened $14.25/share offer for HGSI, cheering Rockville-area diners.
Swing for the Fences With These 5 Biotech Stocks
If you're prepared for the very high stakes and high risks of biotech investing, these five biotech stocks might be worth your while.
Merck Could Have a Home Run in Sight
Merck’s new drug odanacatib can be thanked for the stock's recent rally, but there are two questions that need to be answered.
Investors Bag the Groceries: Thursday’s IP Market Recap
Markets were down as continued worries about Europe and another round of disappointing earnings and guidance pushed prices lower.
How Healthy Is WellPoint’s Amerigroup Deal?
The move, which is likely to be followed, is a big bet that states will allow for Medicaid expansion. If that happens, WellPoint will be well off. But if not ...
Let Cerner Fall Into Your Lap
Use Cerner’s high volatility to your advantage and buy on a pullback. Get the buy price for CERN.
4 ETFs to Guard Against Market Volatility
Worried about the market's current uncertainty? A good defensive play right now is low-risk, low-beta ETFs. Here are four of the best.
Medidata Solutions a Strong Buy in Cloud Computing
Medidata Solutions is a fast-growing cloud services provider to the health care industry that is poised for even better growth and is a buying opportunity
Glaxo to Pay $3B in Fines for Improper Drug Marketing
GlaxoSmithKline will pay $3 billion in fines relating to its promotion of the antidepressant drugs, Paxil, Wellbutrin and Avandia, and the asthma drug Advair.
5 Stocks to Avenge a Bad Court Ruling
Healthcare stocks are a good play right now to take advantage of pockets created by the recent Supreme Court ruling. Here are 5 to start with for investors.
Should I Buy Bristol-Myers Squibb? 3 Pros, 3 Cons
Its deal to buy diabetes-drug maker Amylin will help, given that market's potential. Still, patent expirations loom large and won't be easily overcome.
The Good and Bad in Health Care Industry Sectors
The health care industry is large and varied, and you should know what players have good prospects and bad, so here are four segments to look through.
